Dublin, Aug. 09, 2017 (GLOBE NEWSWIRE) -- The "Global In Vitro Diagnostics (IVD) Market: Drivers, Opportunities, Trends and Forecasts: 2014 - 2020" report has been added to Research and Markets' offering.

The global in-vitro diagnostics market is estimated to witness a CAGR of 5.31% during the forecast period 2017-2023. The market is analyzed based on five segments - technology, application, test types, end-users, and regions.

The market is witnessing an emerging trend for noninvasive prenatal testing, next-generation sequencing (NGS), liquid biopsy, and circulating tumor cells test. The markets in India, Brazil, and China are expected to grow at a rapid pace during the forecast period due to the high prevalence of infectious diseases in these countries.

Factors, such as increased sales of POC cardiac markers and increased adoption of DNA probe-based diagnostics are growth opportunities for the market players. The market is witnessing an emerging trend of companion diagnostics, cardiac biomarkers, POC markers, and other novel technologies that are helping in diagnosing the diseases at an early stage with precision. There has been a transition from diagnosis in core laboratories to diagnosis in front of the patient.The global IVD market is segmented by the following technologies- immunoassay, clinical chemistry, clinical microbiology, molecular diagnostics, hematology, and coagulation.

The clinical chemistry market is currently leading the market with a share of 32.2% due to the high prevalence of diabetes. India has the highest rate of diabetes, making Asia Pacific the region for future investments. The molecular diagnostics segment is expected to have the fastest growth rate during the forecast period. Technological advancements in various molecular diagnostics technology, such as PCR and NGS, are driving the market. The market is also witnessing various M&A and collaborations among the top players, which are defining the future of the global IVD market.

The leader in IVD market is F. Hoffmann-La Roche, who is currently occupying 20% of the IVD market. Abbott, Siemens, Danaher, and ThermoFisher are the other major players in the market. These top players occupy around 56% of the market.Large players, such as F. Hoffmann-La Roche, Danaher, and Abbott, are acquiring companies with products that would complement their existing portfolio.

For instance, in November 2016, Danaher acquired Cepheid and in February 2016, Abbott signed an agreement to acquire Alere, a leader in POC technology. Furthermore, most of the companies are aiming to obtain a waiver of the Clinical Laboratory Improvement Amendments of 1988 for their products to increase their sales. Significant investments in R&D in this market is expected to increase, and collaborations and M&A are expected to continue.

Key Topics Covered:

1 Industry Outlook

2 Report Outline

3 Market Snapshot

4 Market Outlook

5 Market Characteristics
5.1 Evolution
5.2 In-Vitro Diagnostics Advantages
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Lifestyle Diseases
5.3.1.2 Growing adoption of Point-of-Care testing
5.3.1.3 Increasing Demand for Biomarker Based Tests
5.3.1.4 High Growth of Market in Emerging Countries
5.3.2 Opportunities
5.3.2.1 Growing Significance of Companion Diagnostics
5.3.2.2 Increased Number of Mergers and Acquisitions
5.3.2.3 Increased Sales of POC Cardiac Markers
5.3.2.4 Increased Adoption of DNA Probe-based Diagnostics
5.3.3 Restraints
5.3.3.1 Stringent regulatory approvals
5.3.3.2 Increased sales of counterfeit glucose monitoring strips
5.3.4 DRO - Impact Analysis
5.3.5 Key Stakeholders

6 By Technology: Market Size and Analysis
6.1 Overview
6.2 Immunoassay
6.2.1 Enzyme-Linked Immunosorbent Assay (ELISA)
6.2.2 Radioimmunoassay (RIA)
6.2.3 Western Blot
6.3 Clinical Chemistry
6.3.1 Metabolic Panel
6.3.2 Electrolyte Panel
6.3.3 Liver Profile
6.3.4 Renal Panel
6.3.5 Lipid Profile
6.3.6 Thyroid Function Panel
6.3.7 Specialty Chemistry Tests
6.4 Molecular Diagnostics
6.4.1 Polymerase Chain Reaction (PCR)
6.4.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4.3 Microarray
6.4.4 Hybridization
6.4.5 DNA Sequencing
6.4.6 Other MDX technology
6.5 Clinical Microbiology
6.6 Hematology
6.7 Coagulation
6.8 Other IVD Technology

7 By Application: Market Size and Analysis
7.1 Overview
7.2 Oncology
7.3 Diabetes
7.4 Infectious Diseases
7.5 Cardiology
7.6 Autoimmune Disease
7.7 Drug Testing
7.8 Nephrology
7.9 Others

8 Test Types: Market Size and Analysis
8.1 Overview
8.2 Core Laboratories Diagnostics
8.3 Point-of-Care Diagnostic

9 End User: Market Size and Analysis
9.1 Overview
9.2 Hospitals
9.3 Laboratories
9.4 Home Care
9.5 Academics
9.6 Others

10 Regions: Market Size and Analysis

11 Competitive Landscape

12 Vendor Profiles
12.1 F.Hoffmann-La Roche Ltd
12.2 Abbott Laboratories
12.3 Siemens Healthineers Inc.
12.4 Danaher Corporation.
12.5 Thermo Fisher Scientific Inc.
12.6 Sysmex Corp.

13 Companies to Watch For
13.1 Becton Dickinson and Company
13.2 Ortho Clinical Diagnostics (Carlyle Group)
13.3 Bio-Rad Laboratories, Inc.
13.4 Qiagen NV
13.5 BioMerieux S.A.

For more information about this report visit https://www.researchandmarkets.com/research/r7cppm/global_in_vitro

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: In Vitro Diagnostics